INVITED RESEARCH HIGHLIGHT
Year : 2014  |  Volume : 16  |  Issue : 5  |  Page : 664-665

Does tadalafil prevent erectile dysfunction in patients undergoing radiation therapy for prostate cancer?


Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, 3000 CA, The Netherlands

Correspondence Address:
Luca Incrocci
Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, 3000 CA
The Netherlands
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1008-682X.133324

Rights and Permissions

A recently published paper addressed the interesting topic of prevention of erectile dysfunction (ED) with tadalafil, a phosphodiesterase-type 5 inhibitor (PDE5i) in patients undergoing radiation therapy for localized prostate cancer. [1] Tadalafil 5 mg or placebo was administered once-daily for 24 weeks in patients undergoing external-beam radiotherapy (EBRT) or brachytherapy (BT) for prostate cancer. This randomized trial did not show superior efficacy of the active drug compared with placebo 4-6 weeks after stopping the study drug. Furthermore, patients younger than 65 years did not respond significantly better than older patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2863    
    Printed71    
    Emailed1    
    PDF Downloaded450    
    Comments [Add]    
    Cited by others 1    

Recommend this journal